Pre-Market Highlight of the Day: Questcor Pharma, PDL BioPharma, Amgen, and BioCryst Pharma PR Newswire LONDON, January 3, 2014 LONDON, January 3, 2014 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Thursday, January 02, 2013, the US equity market posted losses as the S&P 500 ended the day at 1,831.98, down 0.89%; the Dow Jones Industrial Average closed at 16,441.35, down 0.82%; and the NASDAQ Composite finished at 4,143.07, down 0.80%. The S&P 500 Health Care Sector Index has fallen by 0.55% to end the day at 638.75. However, the S&P 500 Biotechnology Industry Index ended the day at 2,821.11, up 0.65%; and the same has advanced 1.21% in the last one month and 9.03% in the previous three months, compared to a gain of 1.45% and 8.08% in the S&P 500 during the respective periods. The major movers in the industry included Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), PDL BioPharma Inc. (NASDAQ: PDLI), Amgen Inc. (NASDAQ: AMGN), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). All these companies are tracked by AAAResearchReports.com. Free technical research on QCOR, PDLI, AMGN, and BCRX can be downloaded upon signing up at: http://www.aaaresearchreports.com/register/ On Thursday, shares in Questcor Pharmaceuticals Inc. ended the day at $55.19, which is 1.36% higher than the previous day's closing price of $54.45. The company's shares vacillated between $53.75 and $55.24 during the trading session. A total of 0.87 million shares were traded, which is below the daily average volume of 2.07 million. The company's shares have fallen by 6.06% in the last one month and 6.33% in the previous three months, underperforming the S&P 500, which has gained 1.45% and 8.08% during the respective periods. Additionally, Questcor Pharmaceuticals Inc.'s stock is trading above its 200-day moving average of $50.61. Sign up and read the complimentary report on QCOR at: http://www.AAAResearchReports.com/QCOR010314.pdf PDL BioPharma Inc.'s stock gained 1.18% on Thursday, closing the day at $8.54. The company's shares fluctuated between $8.36 and $8.64 during the trading session. A total of 2.54 million shares were traded, which is above the daily average volume of 2.39 million. The company's shares have gained 1.79% in the previous three trading sessions and 7.15% in the last three months, compared to a loss of 0.51% and a gain of 8.08% in the S&P 500 during the respective periods. Furthermore, PDL BioPharma Inc.'s stock is trading above its 200-day moving average of $8.06. The free report on PDLI can be downloaded by signing up now at: http://www.AAAResearchReports.com/PDLI010314.pdf On Thursday, Amgen Inc.'s stock advanced to finish the day at $115.80, up 1.50% from the previous day's closing price of $114.08. The company's shares oscillated between $114.06 and $116.19 during the trading session. A total of 2.53 million shares were traded, which is below the daily average volume of 2.98 million. The company's shares have advanced 1.16% in the last one month and 2.42% in the previous three months, underperforming the S&P 500, which has gained 1.45% and 8.08% during the respective periods. Further, Amgen Inc.'s stock is trading above its 50-day and 200-day moving averages of $114.3 and $108.18, respectively. A free report on AMGN can be accessed by registering at: http://www.AAAResearchReports.com/AMGN010314.pdf Shares in BioCryst Pharmaceuticals Inc. surged on Thursday, hitting a new 52-week high of $8.03. The company's stock ended the day at $7.90, up 3.95% from the previous day's closing price of $7.60. A total of 1.25 million shares were traded, which is above the daily average volume of 0.94 million. The company's shares have gained 5.33% in the previous three trading sessions and 25.00% in the last one month, outperforming the S&P 500, which has fallen by 0.51% and has gained 1.45% during the respective periods. Moreover, BioCryst Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $6.17 and $4.25, respectively. Register with AAA Research Reports and download research on BCRX for free at: http://www.AAAResearchReports.com/BCRX010314.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID: firstname.lastname@example.org
Pre-Market Highlight of the Day: Questcor Pharma, PDL BioPharma, Amgen, and BioCryst Pharma
Press spacebar to pause and continue. Press esc to stop.